Peptide aromatic interactions modulated by fluorinated residues: Synthesis, structure and biological activity of Somatostatin analogs containing 3-(3',5'difluorophenyl)-alanine by Martín-Gago, Pablo et al.
1Scientific RepoRts | 6:27285 | DOI: 10.1038/srep27285
www.nature.com/scientificreports
Peptide aromatic interactions 
modulated by fluorinated residues: 
Synthesis, structure and biological 
activity of Somatostatin analogs 
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alanine
Pablo Martín-Gago1,*, Álvaro Rol1,*, Toni Todorovski1, Eric Aragón1, Pau Martin-Malpartida1, 
Xavier Verdaguer1,2, Mariona Vallès Miret3, Jimena Fernández-Carneado3, Berta Ponsati3, 
Maria J. Macias1,4 & Antoni Riera1,2
Somatostatin is a 14-residue peptide hormone that regulates the endocrine system by binding to five 
G-protein-coupled receptors (SSTR1–5). We have designed six new Somatostatin analogs with L-3-
(3′,5′-difluorophenyl)-alanine (Dfp) as a substitute of Phe and studied the effect of an electron-poor 
aromatic ring in the network of aromatic interactions present in Somatostatin. Replacement of each 
of the Phe residues (positions 6, 7 and 11) by Dfp and use of a D-Trp8 yielded peptides whose main 
conformations could be characterized in aqueous solution by NMR. Receptor binding studies revealed 
that the analog with Dfp at position 7 displayed a remarkable affinity to SSTR2 and SSTR3. Analogs 
with Dfp at positions 6 or 11 displayed a π-π interaction with the Phe present at 11 or 6, respectively. 
Interestingly, these analogs, particularly [D-Trp8,L-Dfp11]-SRIF, showed high selectivity towards 
SSTR2, with a higher value than that of Octreotide and a similar one to that of native Somatostatin.
Somatostatin (somatotropin release-inhibiting factor or SRIF) is a natural peptide hormone involved in multiple 
biological functions1. Although it has a pharmacological application as an anti-secretory drug, its use in growth 
hormone secretion disorders and in endocrine tumor treatment is hampered by its short half-life (2–3 min in 
plasma)2–5. The biological activity of Somatostatin is mediated by its high binding affinity to five structurally 
related G-protein-coupled receptors, named SSTR1–56,7. The pioneering work of Vale et al.8 established that resi-
dues 7 to 10 form the pharmacophore region of Somatostatin. This finding fostered the development of a myriad 
of short-ring analogs, Octreotide (Sandostatin® )9,10 being the most successful, although others such as Lanreotide 
(Somatuline® )11, Vapreotide (Sanvar® )12, and Pasireotide (Signifor® )13 have also reached the market. Structural 
studies of short-ring analogs have been performed using NMR and X-ray techniques14–18. In addition, early 
NMR studies on the 14-amino acid native hormone identified an aromatic interaction between Phe6 and Phe11 
(Fig. 1)19; however, the structure of the hormone could not be determined in solution due to the presence of sev-
eral conformations in equilibrium20,21. In a project devoted to finding new Somatostatin analogs with improved 
stability and selectivity, we found that the replacement of one of the Phe residues in the 14-residue sequence 
by Msa (3-mesitylalanine) resulted in highly selective compounds22. Moreover, some of these new 14-residue 
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peptides showed high conformational stability (particularly those that also had a D-Trp in position 8), thereby 
allowing the determination of their 3D structures by NMR for the first time, in a similar way as previous studies 
devoted to short-ring analogs, including Octreotide. These structures confirmed the relevance of non-covalent 
interactions between aromatic residues in positions 6, 7 and 11 in the modulation of the conformation and bind-
ing behavior of the correspondent Somatostatin analogs22–24.
Site-directed introduction of fluorinated amino acids has become an increasingly attractive approach in pro-
tein and peptide engineering25. Fluorinated amino acids cause minimal perturbation of the parent structures, 
but favor protein folding and stability due to their increased aromatic stacking and hydrophobicity26. However, 
to the best of our knowledge, the effect of introducing fluorinated Phe residues in the context of Somatostatin 
has not been addressed to date27. One of the few reports of Somatostatin analogs containing electron-poor aro-
matic residues as Phe isosteres was done by Hirschmann and co-workers28, who synthesized analogs containing 
L-pyrazinylalanine (Pyz).
In order to explore the role of aromatic interactions in the structure and function of Somatostatin analogs 
and to design new selective and stable compounds, we substituted the Phe amino acids of the natural sequence 
for fluorinated derivatives. The logic of this substitution involves the application of electron-poor aromatic 
side-chains (such as fluorinated phenylalanine), thus favoring the association with the electron-rich ring of native 
Phe residues. To test this hypothesis, we selected the L-3-(3′ ,5′ -difluorophenyl)alanine (Dfp) from the fluori-
nated amino acids available. Since we aimed to characterize these interactions using NMR, the Dfp analog has 
the advantage that its aromatic ring still holds three hydrogen atoms—a valuable feature that provides structural 
information via NOE interactions with neighboring residues. Here we describe the synthesis and NMR structures 
of six new Somatostatin analogs containing Dfp amino acid. We also analyze the binding preferences of these new 
analogs with respect to SSTR1–5.
Results
Design of six new Somatostatin analogs (peptides 1–6). Most of the Somatostatin analogs devel-
oped to date are short-ring cyclic peptides that contain the pharmacophore region comprising the residues —
FFWKTF— of the hormone. In contrast, our approach was to introduce small modifications into its natural 
14-amino acid sequence, since the remaining amino acids also play a role in the biological activity of the hor-
mone22. All our peptides were designed to contain a D-Trp because the replacement of L-Trp in position 8 by its D 
enantiomer enhances the stability of the analogs while maintaining similar binding affinities2,29–32. The sequences 
of the six analogs studied herein are shown in Fig. 1. In the first group, we replaced, one by one, Phe6, Phe7 and 
Phe11, respectively, by Dfp (peptides 1–3). We previously observed that replacing Phe7 by Msa favors the aro-
matic interaction between the benzene rings of Phe6 and Phe1122. Therefore, we designed two more analogs that 
combined Msa in position 7 and Dfp in positions 6 or 11 (peptides 4 and 5). Finally, an analog with both Phe6 
and Phe11 replaced by Dfp (peptide 6) was also synthesized in order to test the effect of two fluorinated residues 
in the presence of Msa7.
Synthesis of Fmoc-L-Difluorophenylalanine (Fmoc-L-Dfp-OH) and the six peptides. Dfp was 
synthesized starting from 3,5-difluorobenzaldehyde, as described in Fig. 2a. The azlactone (1) was obtained by 
treatment with N-acetylglycine and the subsequent ring-opening reaction with (MeONa/MeOH) produced the 
(Z)-methyl-2-acetamido-3-(3′ ,5′ -difluorophenyl)acrylate (2) in 58% overall yield (> 10 g scale). The (E)-isomer 
was not detected by TLC or by 1H-NMR. Using an asymmetric hydrogenation reaction with [Rh(S-MaxPHOS)
(cod)]BF433,34 as hydrogenation catalyst, we prepared the acetamido ester (3) with 99% ee (S)-enantiomer. 
Figure 1. Sequences of Somatostatin and Octreotide and of the six Somatostatin analogs synthesized in 
this work. For simplicity, the disulfide bridge present in these molecules is displayed only on the top of the 
Somatostatin and Octreotide sequences. The modified amino acids are depicted as colored rectangles, yellow for 
D-Trp, blue for L-Dfp, red for L-Msa, gray for D-Phe, and purple for L-Thr-ol. The pharmacophore region of the 
native hormone and of all analogs is highlighted in green.
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Fmoc-L-Dfp-OH was obtained in excellent yield and optical purity after acid hydrolysis of (3) (to give 4) and 
final Fmoc-protection22. Peptides 1–6 (Fig. 1) were prepared by standard Fmoc/tBu solid-phase peptide synthesis 
(SPPS)35 using 2-chlorotrityl chloride resin22–24. The schematic representation of the synthetic strategy used for 
the six peptides is shown in Fig. 2b. TFA salts of the purified peptides were used in the NMR studies, but the TFA 
anions were exchanged for acetates prior to receptor binding studies.
Affinities of the new Somatostatin analogs towards SSTR1–5. For each peptide 1–6, the binding 
affinity towards SSTR1–5 was measured by a competitive binding assay using 125I-labeled Somatostatin-14 and 
various concentrations of each unlabeled ligand, respectively, in triplicate. For comparative purposes, the same 
test was applied to Somatostatin and Octreotide. The Ki values were calculated using the Cheng and-Prusoff 
equation (Table 1)36. The receptor-subtype selectivity profiles of these analogs will be discussed in detail in parallel 
with the details of the structural studies.
NMR studies of Peptides 1–6. Lyophilized peptides were dissolved and neutralized in aqueous solution 
(1 mM concentration) and analyzed by NMR. In all cases, well-dispersed two-dimensional NOESY and TOCSY 
homonuclear experiments showed a major set of NOE peaks, whose assignments enabled us to characterize the 
main conformations of the peptides in solution. Structures were generated using the Crystallography & NMR 
System (CNS)37 protocols.
[L-Dfp6,D-Trp8]-SRIF (peptide 1). The 2D NMR spectra showed a large number of NOE signals that have 
been unambiguously assigned. This information was used as restrictions to characterize the most populated con-
formations for this peptide in aqueous solution. These conformations are shown in Fig. 3a as a superimposition 
of a family of conformations ordered on the basis of their energy. The most remarkable features of this family of 
conformations were the hairpin involving residues 6–11 and the aromatic stacking between Dfp6 and Phe11. 
The hydrophobic interaction between D-Trp8 and Lys9, which further stabilizes the hairpin area, was defined by 
numerous proton-proton contacts between these two residues. In addition, most of the NOE contacts displayed 
by the Dfp6 side-chain were with the Phe11 side chain (Hδ of Phe11 with the Hα , Hβ 2, Hβ 3 and Hδ of Dfp6 and 
Figure 2. Schematic representations of the Dfp synthesis and the synthetic protocol used for the 
preparation of peptides 1–6. (a) Synthesis of Fmoc-L-Dfp-OH. a) N-Ac-Gly-OH, AcONa, Ac2O, 2 h, 100 °C; 
b) MeONa, MeOH, 2 h, 70 °C; c) [Rh(S-MaxPHOS)(COD)]BF4 cat 3%, H2 (5 bar), MeOH, r.t.; d) HCl aq, 6 h, 
reflux; e) FmocOSu, Na2CO3, H2O, acetone, 0 °C to r.t.; (b) General schematic synthesis pathway for peptides. a) 
1. Fmoc-L-Cys(trt)-OH (3 eq.), DIPEA (4 eq.), 2. MeOH; b) 1. Piperidine 20% DMF, 2. Fmoc-Aaa-OH (1.5–3 
eq.), DIPCDI (3 eq.), HOBt (3 eq.), DMF, c) CH2Cl2/TFE/AcOH, d) 1. I2, 2. TFA/CH2Cl2/anisole/H2O.
SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Somatostatin (SRIF) 1.88 0.016 0.25 1.55 0.76
Octreotide > 300 0.770 13.0 > 300 21.0
1 [L-Dfp6,D-Trp8]-SRIF 21.0 0.350 0.38 16.0 5.02
2 [L-Dfp7,D-Trp8]-SRIF 14.0 0.360 1.10 12.0 2.10
3 [D-Trp8,L-Dfp11]-SRIF 14.0 0.066 3.81 11.0 5.00
4 [L-Dfp6,L-Msa7,D-Trp8]-SRIF 38.0 0.170 5.46 150 82.0
5 [L-Msa7,D-Trp8.L-Dfp11]-SRIF 19.0 0.260 23.0 62.0 31.0
6 [L-Dfp6,11,L-Msa7,D-Trp8]-SRIF 55.0 0.310 12.0 63.0 45.0
Table 1.  Ki values (nM) of Somatostatin, [D-Trp8]-SRIF, Octreotide, and Somatostatin analogs to 
receptors SSTR1–5. Shaded cells represent data close to the Somatostatin values. The binding measurements 
were performed by Eurofins Panlabs Taiwan, Ltd.
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Hε of Phe11 with Hβ 2, Hβ 3, Hδ and Hζ of Dfp6). The π − π interaction between Dfp6 and Phe11 was found to 
belong to the offset-stacked type, but the aromatic rings were not oriented parallel to one another. As previously 
described in the models reported by Hunter and Sanders38 and by Cozzi, Siegel et al.39, the poor π -electron den-
sity of the difluorophenyl ring reduced the electrostatic repulsion between the π -electron clouds of Dfp6 and 
Phe11, thereby enhancing the π -stacking interaction between them. In peptide 1, the Phe7, placed at the opposite 
side of the molecule, did not participate in these aromatic interactions. Indeed, the aromatic ring of Phe7 has 
contacts with the Hβ 2 of Asn5 and with the Qγ 2 methyl groups of Thr10 and Thr12. Consequently, the conforma-
tions of peptide 1 are more restricted than the counterpart without the fluorine substitution (D-Trp8-SRIF) pre-
viously analyzed22. The binding profile of peptide 1 showed strong affinity to SSTR2, similar to that of Octreotide, 
and remarkable affinity to SSTR3, in the same order as Somatostatin.
[L-Dfp7,D-Trp8]-SRIF (peptide 2). The NMR data obtained for this peptide also showed remarkable con-
formational stability, thereby allowing the determination of its 3D structure in solution (Fig. 3b). In striking 
contrast to the previous structures, the lower energy conformations of peptide 2 showed all aromatic residues 
located on the same side of the molecule. The Dfp7 residue showed several NOE contacts with the Phe6 and 
Phe11 side-chains and result in an edge-to-face orientation of the aromatic rings. These NOEs were unambigu-
ously assigned and involved the Hδ of Dfp7 and the Hα and Hβ 2/β 3 of Phe6 and also between the aromatic ring 
of Phe11 with the beta protons of Phe6 and Dfp7. The NMR data indicated that the aromatic side-chain of Dfp7 
occupies a position near to the D-Trp8 residue. In order to increase the aromatic interactions with the fluorinated 
residue in 7, residues 6 and 11, moved from the top to the bottom of the molecule (according to the orientation 
shown in the Fig. 3b), probably due to the stronger π − π stacking tendency of the difluorobenzene ring. The 
indole ring displayed numerous NOE signals with the aliphatic side-chain of Lys9 as a result of the stabilizing 
effect of the D-Trp8-Lys9 hydrophobic interaction. Somewhat surprisingly, although the overall geometry of pep-
tides 1 and 2 differed greatly, these molecules showed a similar binding profile. The affinity of these two peptides 
for SSTR2 was similar to that of the Octreotide used for comparison purposes.
[D-Trp8,L-Dfp11]-SRIF (peptide 3). The NMR data corresponding to this analog also displayed an abun-
dant number of NOEs, thereby allowing us to calculate a family of well-defined 3D structures (Fig. 3c). NOEs 
between Phe6 and Dfp11 were both abundant and intense, indicating close proximity of their side-chains in 
solution. The aromatic moieties of these residues were engaged in a parallel offset-stacked aromatic interaction in 
Figure 3. Superimposition of the 20 best conformers selected on the basis of the low energy values of the 
six Somatostatin analogs, namely peptide 1–6 (shown as panels a to f respectively). Next to these figures we 
show their π − π aromatic interaction between aromatic residues in position 6 and 11. Residues are highlighted 
by position.
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which the most negatively charged part of the Dfp11 ring pointed away from the π -cloud of the native Phe6. This 
ring orientation, defined by several NOE contacts between Dfp11 and the side-chains of Lys4, Phe6, Thr12 and 
Ser13, was similar to that of the aromatic interaction between Dfp6-Phe11 in peptide 1. In these cases, the Phe7 
aromatic side-chain was accommodated on the other side of the molecule, thus facilitating the aromatic interac-
tion between Phe6 and Dfp11. This analog displayed high affinity and selectivity towards SSTR2, presenting Ki 
values similar to Somatostatin, and improving that of Octreotide (Table 1).
[L-Dfp6,L-Msa7,D-Trp8]-SRIF (peptide 4). In previous studies22, we reported that the presence of a mes-
ityl residue in position 7 enhances the π − π interaction between aromatic residues 6 and 11, thus providing more 
conformationally restricted peptides with high SSTR2 affinity. With the aim of reinforcing the Dfp6-Phe11 inter-
action, we designed a new analog including the Msa substitution at position 7. However, peptide 4 showed greater 
conformational mobility than expected, as revealed by NMR data. The π − π -aromatic interaction between Dfp6 
and Phe11 was present with the offset-stacked displacement of the rings more pronounced than in the absence of 
Msa7 (Fig. 3d). The angle between rings was closer to an offset-stacked parallel geometry. As we have observed in 
other peptides, the Msa7 residue did not participate in the aromatic interactions with residues 6 and 11, since it 
was placed at the opposite side of the molecule. However, in peptide 4, the mesityl ring was oriented towards the 
center of the molecule, as the equivalent phenylalanine of peptide 1. The affinity for SSTR3 dropped one order of 
magnitude compared to peptide 1, whereas that towards SSTR2 increased. Overall, the geometry of peptide 4 was 
similar to that of Somatostatin analogs with Msa in position 7, previously described by our group22–24. The main 
difference was that the π − π interaction was now offset-stacked instead of edge-to-face. Analog 4 showed high 
selectivity toward SSTR2 (with a Ki value in the same range as that of Octreotide), although its binding affinity 
was not as high as in the [Msa7,D-Trp8]-SRIF analog reported previously22. Nevertheless, the presence of Msa7 
improved the pharmacological profile of the molecule since it increased selectivity towards SSTR2 by decreasing 
affinity to SSTR4 and SSTR5.
[L-Msa7,D-Trp8,L-Dfp11]-SRIF (peptide 5). The NMR data corresponding to the substitution of Phe7 
for its Msa7 counterpart in the peptide 3 scaffold showed high conformational rigidity by NMR, thus allowing the 
identification of a set of low energy conformers superimposed and displayed in Fig. 3e. These structures showed 
that Dfp11 and Phe6 adopt an aromatic face-to-face orientation defined by an abundant set of unambiguously 
identified NOEs. Interestingly, peptide 5 had residues 6 and 11 on the opposite side with respect to the orientation 
observed for peptide 3. Indeed, the general structure of 5 differed greatly from those characterized for peptides 1 
and 4. The binding of peptide 5 to SSTR2, SSTR3 and SSTR5 decreased by one order of magnitude with respect 
to that of peptide 3. This observation may be attributed to the aforementioned differences. However, peptide 5 
was still relatively selective for SSTR2 (with a Ki of the same order of magnitude as Octreotide). As occurred with 
peptide 4, the replacement of Phe7 by Msa decreased the binding capacity to SSTR4 and SSTR5 with respect to 
the results obtained with peptide 3.
[L-Dfp6,11,Msa7,D-Trp8]-SRIF (peptide 6). We also examined the effect of replacing both Phe6 
and Phe11 by Dfp residues, maintaining the Msa7 and D-Trp8 residues, on the binding specificities of the 
Somatostatin analogs. On the basis of the NMR data, and despite the number of substitutions introduced, this 
peptide folded with the characteristic orientation that maintains residues 6 and 11 on one face of the structure and 
the Msa7 on the other—similar to the postulated SSTR2—bioactive conformation of Somatostatin22. A family of 
conformers selected on the basis of lower energy values were superimposed and are shown in Fig. 3f. The interac-
tion between the pair of Dfp6 residues, which are more hydrophobic and electron-poor aromatic rings than the 
Phe6-Phe11 phenylalanine pair, provided more stabilization than the interaction present in the parent compound. 
This observation is in agreement with the electrostatic26 and the polar/π 27 model where electron-withdrawing 
substituents enhance the π -stacking interactions because they decrease the aryl π -electron density, thus minimiz-
ing repulsion between two electron-poor rings. However, receptor-subtype assays for this analog revealed strong 
selectivity towards SSTR2 (probably induced by the presence of Msa7, which by itself decreases binding to SSTR4 
and SSTR5) but at a similar level to that of peptides 4 and 5.
Discussion
Here we studied the effect of substituting Phe residues for Dfp (3-(3′ ,5′ -difluorophenyl)-alanine) in the 14 amino 
acid structure of Somatostatin containing a D-Trp in position 8. All six peptides displayed well-dispersed 2D 
NMR data, which were used to characterize their main conformations in aqueous solution. It has been postulated 
that electron-deficient aromatic residues in position 11 destabilize the fold of the analog due to their limited 
capacity to shield the natural Phe625. However, we found that the Somatostatin analog [D-Trp8,Dfp11]-SRIF 
(peptide 3) showed a strong interaction between the aromatic rings of Phe6 and Dfp11, and remarkably high 
activity and selectivity towards SSTR2. Interestingly, when the Dfp residue was placed in position 7 (peptide 2), 
the analog displayed high affinity and selectivity for SSTR3.
Several studies using short-ring Somatostatin analogs have correlated the selectivity towards a given receptor 
type with the 3D conformations of the analogs14–18. For instance, the structure of Octreotide has been deter-
mined by X-ray40 and NMR41 and is considered one of the preferred conformations recognized by SSRT217,18. 
NMR studies of other short-ring analogs revealed the presence of conformations preferentially recognized by 
SSTR115, SSTR316 and SSTR414. Indeed, it is widely accepted that the geometry of the peptide backbone in the 
pharmacophore region plays an important role in receptor recognition18. In order to compare the similarities 
and differences of these new analogs to others previously characterized, we collected the structural information 
on SSTR2- and SSTR3-selective binders from the literature. The comparison focused on the psi (Ψ ), phi (Φ ), and 
chi1 (Χ1) angles in the pharmacophore and on five representative analogs selected on the basis of their binding 
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preferences (Fig. 4a). The analysis also included peptides 1–3, whose affinities for SSTR2 and SSTR3 are in the 
range of the Somatostatin hormone. As expected, since most of the analyzed conformers displayed a beta-turn 
structure, there was a high degree of similarity with respect to the Ψ and Χ1 values, whereas the variability was 
slightly larger for the Φ angle, especially in the case of the residue occupying the Tryptophan position.
In order to explore the similarities and differences of the pharmacophore region at the side-chain level, we 
superimposed the 3D structure of Octreotide (PDB ID 1SOC) on the structures of peptides 1 and 3 (Fig. 4d). 
The comparison revealed a striking similarity, not only around the beta-turn area but also in the position of the 
aromatic rings, where the Phe1 and Phe3 of Octreotide are located in a similar position to Phe7 in the 14-residue 
analogs (and presumably in the natural hormone). These similarities could explain the high affinity of Octreotide 
and peptides 1 and 3 for SSTR2. However, these comparisons also revealed small differences at the backbone 
and at the side-chain levels. These differences with the Octreotide structure (Fig. 4b) were more significant for 
peptides 1 and 2, which displayed similar affinity values for SSTR2 and SSTR3, than for peptide 3, which showed 
Figure 4. Comparison of representative angles and structures of some Somatostatin analogs. (a) 
Comparison of Φ , Ψ and Χ1 angles defining the pharmacophore region. The positions used for the analysis are 
represented with the amino acids corresponding to the native sequence of Somatostatin (-FFWKTF-), which 
are shown as a guideline. The plots show the dihedral angles of eight representative analogs (including peptides 
1, 2 and 3) of SSTR2 and SSTR3 binders: OCTR: Octreotide, D-Phe,c[Cys,Phe,D-Trp,Lys,Thr,Cys],Thr-ol, 
(Melacini et al.41) PEPT1: peptide 1, [L-Dfp6,D-Trp8]-SRIF), PEPT2: peptide 2, [L-Dfp7,D-Trp8]-SRIF), 
PEPT3: peptide 3, [D-Trp8,L-Dfp11]-SRIF), GCR-SSTR2 (H2N-CO-D-Phe,c[Cys,Aph(CONHOCH3),D-
Trp,Lys,Thr,Cys],Thr-NH2 (Grace et al.17), GM-SSTR3 (c[Cys,Phe,Tyr,Agl,Lys,Thr,Phe,Cys] (Gairí et al.16), 
NGV-SSTR2 and NGV-SSTR3 (D-Phe,c[Cys,Phe,D-Trp,Lys,Thr,Cys],Thr-NH2) and D-Phe,c[Cys,Phe,D-
Trp,Lys,Thr,Cys],Thr-NH2 (Nikiforovich et al.18). (b) The lowest energy structures of peptide 1 (receptor 2 
and 3 binder) and peptide 3 (receptor 2 binder), shown in purple and green respectively, with the side chains 
of selected amino acids displayed and labeled. The structure of the minimized average beta-sheet structure of 
Octreotide (PDB ID: 1SOC, Melacini et al.41) is shown in gold. (c) Structural alignment of peptide 1 and 3 to 
Octreotide, showing the RMSD difference in arbitrary units (generated with Chimera). X1 = L-Dfp (L-3-(3′ 
,5′ -difluorophenyl)alanine), X2 = D-Trp, X3 = D-Phe, X4 = L-Thr(ol). (d) Superposition of the structures of 
peptide 1 (top) and 3 (bottom) with Octreotide.
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greater affinity and selectivity towards SSTR2. Some of these differences may explain the preferential binding of 
peptides 1 and 2 to SSTR3.
In summary, here we have optimized an efficient method for preparing the Dfp amino acid with a 99% ee 
and designed, synthesized, and structurally characterized six new 14-residue Somatostatin analogs. Peptide 3, 
[D-Trp8,Dfp11]-SRIF, had the highest activity and selectivity for SSTR2, the values being higher than those of 
Octreotide and similar to those of the natural hormone. In addition, peptide 1 ([Dfp6,D-Trp8]-SRIF) and peptide 
2 ([Dfp7,D-Trp8]-SRIF), whose conformations in solution differ in their aromatic packing, both showed high 
activity towards SSTR2 and SSTR3. Our work indicates that Dfp amino acids are efficient building blocks in the 
synthesis of peptide analogs and opens up new possibilities for designing molecules with tuned selectivity and 
specificity towards SSTR2 and SSTR3.
Methods
Synthesis. Fmoc-Dfp-OH was prepared as shown in Fig. 2a. Experimental details can be found in the sup-
porting information.
The synthesis of peptides 1–6 was performed by SPPS on a 2-Cl-Trt chloride resin (0.80–1.60 mmol/g) using 
the Fmoc/tBu strategy (Fig. 2b). Initially, the first amino acid Fmoc-L-Cys(Trt)-OH (1 eq.) was coupled in the 
presence of DIPEA (4 eq.) in DCM as solvent for 40 min and finally end-capped with methanol (0.8 mL.g−1). 
Fmoc was then removed by treating the peptidyl resin with 20% piperidine in DMF (1 × 1′ and 1 × 5′ ). The 
second amino acid Fmoc-L-Ser(tBu)-OH (2.5 eq.) was coupled in DMF for 40–60 min using DIPCDI (2.5 eq.) 
and HOBt (2.5 eq.) as activating reagents. The Kaiser test was used to check coupling completion. This pro-
cedure was repeated for the following 11 Fmoc-protected amino acids and for the last Boc-L-Ala-OH. When 
Fmoc-L-Msa-OH or Fmoc-L-Dfp-OH was coupled, only 1.5 eq. were used. Cleavage of the fully protected linear 
peptide from the resin was carried out using a cleavage cocktail (DCM:TFE:AcOH, 70:20:10 (v/v)) for 2 h. The 
formation of the disulfide bridge in all the analogs was achieved using iodine at room temperature and quenching 
with 1N sodium thiosulfate. The aqueous layer was extracted with DCM (3 × 4 mL), the combined organic layer 
was washed with a mixture of an aqueous citric acid 5% solution/sodium chloride (1:1) and evaporated under 
reduced pressure. Finally, total deprotection of the side-chains was performed using an acidic mixture (TFA/
DCM/Anisole/H2O) for 4 h. The remaining solution was then washed with heptane (20 mL), and the aqueous 
layer was precipitated in Et2O (− 10 °C) to obtain Somatostatin analogs 1–6.
NMR and Computational methods. Spin systems and sequential assignments for all analogs were 
obtained from 2D TOCSY and NOESY homonuclear experiments, recorded at 285 K using a Bruker Avance III 
600-MHz spectrometer equipped with a quadruple resonance z-gradient CryoProbe (5 mm QPQCI). All NMR 
data were processed with NMRPipe42 and Cara43 was used to facilitate the assignment of the spectra. Distance 
restraints derived from fully assigned peaks in NOESY experiments were used for structure calculation. The 
structures were calculated with the program CNS 1.237. The calculation protocol consisted of an implicit water 
simulated-annealing of 120 structures using 8,000 cooling steps followed by an explicit water refinement of the 
calculated structures using all experimental restraints during 1200 steps. PyMOL44 and UCSF Chimera45 were 
used to visualize the structures and generate the figures. BMRB codes for peptides 1-6: 26794, 26795, 26796, 
26707, 26798 and 26799.
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